Mon. 11 Mar 2024, 4:12pm ET
Benzinga
Earnings, Earnings Misses, News
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.30) by 16.67 percent. The company reported quarterly sales of $14.802 million which missed the analyst consensus estimate of $15.707 million by 5.76 percent. This is a 5.16 percent increase over sales of $14.076 million the same period last year.